Deal snapshot: Cortexyme to Acquire Novosteo to Expand Pipeline of Therapeutics into Rare Disease Indications.

MANews-(C)2009-2022

California-based biopharmaceutical company Cortexyme, Inc. (NASDAQ: CRTX) has agreed to acquire Pennsylvania-based biotech company Novosteo, to expand pipeline of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury, the company said.

Upon completion of the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT